Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mesalazine granules versus placebo for prevention of recurrence of diverticulitis
2007-000680-22Phase 3Completed
- Sponsor
- Dr. Falk Pharma GmbH
- Start
- Jul 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in diverticulitis comparing Mesalazine granules 3 g/day with Placebo (2 arms). Primary endpoint: Proportion of recurrence-free patients within 48 weeks. Started Jul 2007; status: completed.
02
Drugs
Salcrozine
03
Conditions
diverticulitis
Beyond the preview
Go deeper on 2007-000680-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000680-22.